EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of GDF-15 in Heart Failure and Biomarker Potential—From Basic Science to Clinical Praxis

Mário Barbosa iD, Maria Ana Martins iD, Joana Fernandes-Silva iD, Ana Melício iD, Álvaro M Martins

Biology · 23.03.2026 · 15 (6) · 516

DOI: 10.3390/biology15060516 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biology, online erschienen am 23.03.2026. Verfasst von Mário Barbosa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Lusíadas Hospital Lisbon, 1500-458 Lisbon, Portugal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure (HF) prognosis, particularly readmission and mortality, remains poor irrespective of advances in its management. Growth differentiation factor-15 (GDF-15) is a member of the transforming growth factor-beta (TGF-β) superfamily that arises as a promising biomarker to improve HF management, still despite two decades of extensive investigation some issues remain controversial. We performed a search in PubMed using the following Medical Subject Headings (MeSH) to identify relevant studies published in the last five years (after the latest updates of the guidelines by major Scientific Societies): “Growth differentiation factor-15 (GDF-15)”, “heart failure”, “prognosis” and “diagnosis”. The search was supplemented by data previous to this period, considered of utmost importance. A total of 115 articles written in English were retrieved. Extensive evidence supports GDF-15 as an independent predictor of adverse outcomes across the heterogeneous HF spectrum and its addition to risk scores based on traditional biomarkers improves prognostic power. However, limited tissue specificity restricts its diagnostic value. Tailored treatment strategies and its role as a therapeutic target remain speculative, as the effect of HF therapies on GDF-15 levels is unclear and clinical trials have been unsuccessful. Large prospective studies are needed to validate its reliability for routine clinical use.

Schlagwörter

Stichwörter der Autor:innen

GDF-15diagnosisheart failureprognosis

Autor:innen und Institutionen

  • Department of Internal Medicine, Lusíadas Hospital Lisbon, 1500-458 Lisbon, Portugal.
  • Faculty of Medicine, University of Lisbon, 1649-028 Lisbon, Portugal.
  • Environmental Health Institute-ISAMB, TERRA Associated Laboratory, 1649-028 Lisbon, Portugal.
  • Department of Internal Medicine II, North Lisbon University Hospital Center-ULS Santa Maria, 1649-028 Lisbon, Portugal.
  • Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal.
  • Institute of Molecular Pathology and Immunology (IPATIMUP), University of Porto, 4200-135 Porto, Portugal.

ORCID-Profile: Mário Barbosa, Maria Ana Martins, Joana Fernandes-Silva, Ana Melício

Zitieren

APA

Barbosa, M., Martins, M. A., Fernandes-Silva, J., Melício, A., & Martins, Á. M. (2026). The Role of GDF-15 in Heart Failure and Biomarker Potential—From Basic Science to Clinical Praxis. Biology, 15(6), 516. https://doi.org/10.3390/biology15060516

Vancouver

Barbosa M, Martins MA, Fernandes-Silva J, Melício A, Martins ÁM. The Role of GDF-15 in Heart Failure and Biomarker Potential—From Basic Science to Clinical Praxis. Biology. 2026;15(6):516. doi:10.3390/biology15060516

BibTeX
@article{Barbosa2026,
  author = {Barbosa, Mário and Martins, Maria Ana and Fernandes-Silva, Joana and Melício, Ana and Martins, Álvaro M},
  title = {The Role of GDF-15 in Heart Failure and Biomarker Potential—From Basic Science to Clinical Praxis},
  journal = {Biology},
  year = {2026},
  volume = {15},
  number = {6},
  pages = {516},
  doi = {10.3390/biology15060516}
}
Kostenlos starten →